Why the study?
Patients with co-morbid heart failure and type 2 diabetes mellitus are at elevated risk of adverse outcomes, making the optimization of complementary drug therapies essential.
Recent advances in drug therapy, particularly sacubitril/valsartan and SGLT2 inhibitors, have the potential to transform the pharmacologic management of co-morbid heart failure and type 2 diabetes.
Optimization of complementary therapies in HF with T2DM may improve outcomes; leaves open optimal strategies pending further trials.
Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease and occurs in ~25% of patients with heart failure (HF). Patients with co-morbid HF and T2DM are at elevated risk of adverse outcomes, making optimization of complementary drug therapies essential. While research is ongoing, recent advances in drug therapy, including the introduction of sacubitril/valsartan for HF with reduced ejection fraction and the finding of positive cardiovascular effects of glucose-lowering agents (particularly sodium-glucose co-transporter-2 [SGLT2] inhibitors) have the potential to transform pharmacologic management of co-morbid HF and T2DM. In this review, we provide a comprehensive overview of cardiovascular clinical trials of therapies for HF and diabetes mellitus to date and identify areas requiring further investigation. We also discuss the pathophysiologic overlap of the two diseases and explore the complementary therapeutic effects of HF and T2DM drugs, with a particular focus on sacubitril/valsartan and SGLT2 inhibitors.
No takes yet. Share an insight, caveat, or question.
Butler et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: